MONOPAR THERAPEUTICS INC

Monopar Therapeutics wins FDA Rare Pediatric Disease status for ALXN1840, boosting investor confidence and speeding Wilson disease drug development.

Monopar Therapeutics’ Phase 3 data show tiomolibdate choline delivers sustained neurological improvement for Wilson disease, setting the stage for an FDA NDA and potential market upside.

Monopar Therapeutics Inc. pioneers oncology drug combos to boost patient outcomes, trading at $82.58 on Nasdaq with a $601 M market cap—discover its research, investor outlook, and global cancer impact.

Monopar Therapeutics Inc.’s stock has experienced significant fluctuations over the past year, closing at $34.505 on June 9, 2025, with a market capitalization of approximately $226.94 million.

Monopar Therapeutics Inc.’s stock has experienced significant fluctuations over the past year, closing at $34.505 on June 9, 2025, with a market capitalization of approximately $226.94 million.

Monopar Therapeutics Inc. is advancing in cancer drug development, with a focus on improving clinical outcomes for patients through innovative research and drug combinations.